Maze Therapeutics names Hervé Hoppenot as board chairman

Maze Therapeutics Inc. (NASDAQ: MAZE) announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors. Hoppenot succeeds Charles Homcy, who will remain on the board.

Hoppenot brings over 30 years of experience in therapeutic development and commercial leadership. He served as Chief Executive Officer of Incyte Corporation from 2014 to 2025 and as Chairman from 2015 to 2025. During his tenure as CEO, Incyte's revenue grew from $350 million to more than $4 billion, according to the company statement.

Prior to Incyte, Hoppenot held senior positions at Novartis, including President of Novartis Oncology and Chief Commercial Officer. He also served in leadership roles at Aventis. Hoppenot currently serves on the boards of Incyte, Laboratoires Pierre Fabre, N-Power Medicine and Bicycle Therapeutics.

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. The company recently completed a $150 million private placement and reported first-in-human data for its drug candidate MZE782.

The company plans to initiate Phase 2 trials for MZE782 in phenylketonuria and chronic kidney disease in 2026. Maze also expects initial Phase 2 data for MZE829, targeting APOL1-mediated kidney disease, in 2026.

Maze's pipeline includes MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 trials. The company is headquartered in South San Francisco.

You May Also Be Interested In

• Intel (INTC) PT Lowered to $92 at Mizuho
• Eikon Therapeutics names new chief scientific officer from Bristol Myers Squibb
• Samsara hits $2.1B in ARR with 30% year-over-year growth